BioMarin Pharmaceutical, NASDAQ and BMRN

Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today
BioMarin Pharmaceutical (NASDAQ: BMRN) was a lively stock in the best way on Thursday following the release of its latest set of quarterly results. Enthusiastic investors traded the company's shares up by nearly 5% in price,
BioMarin Pharmaceutical (NASDAQ:BMRN) Upgraded at StockNews.com
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Saturday.
BioMarin Pharmaceutical (NASDAQ:BMRN) Reports Bullish Q4, Stock Soars
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 15.6% year on year to $747.3 million. The company’s full-year revenue guidance of $3.
Why Is BioMarin Stock Trading Higher On Thursday?
BioMarin exceeded Q4 earnings expectations, raised 2025 guidance, and projected strong Voxzogo growth. Analysts increased price targets following the results.
Wedbush Remains a Buy on BioMarin Pharmaceutical (BMRN)
In a report released today, Yun Zhong from Wedbush maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today
What Happened? Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 9.6% in the pre-market session after the company reported impressive fourth-quarter results, exceeding analysts' sales and EPS estimates.
BioMarin upgraded to Outperform from Perform at Oppenheimer
Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target Discover the Best Stocks and Maximize Your Portfolio: ...
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $113.00
BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price upped by UBS Group from $109.00 to $113.00 in a ...
BioMarin: EPS Surges Past Expectations
BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results.
Oppenheimer upgrades BioMarin with stage set for increasing interest
Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target BioMarin reported strong Q4 results and Oppenheimer ...
FierceBiotech3d
As BioMarin searches for 'clever science,' its R&D chief warns innovation could be hit by NIH fund drought
The R&D head is looking for "clever science," which Friberg said is readily apparent in BioMarin’s recent research pact with CAMP4 Therapeutics. The partners are using CAMP4’s regulatory RNA platform ...
Demystifying Biomarin Pharmaceutical: Insights From 8 Analyst Reviews
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $94.25, a high estimate of $126.00, and a low estimate of $70.00. This current ...
Yahoo Finance4d
Q4 2024 BioMarin Pharmaceutical Inc Earnings Call
Alexander Hardy; President, Chief Executive Officer, Director; Biomarin Pharmaceutical Inc Brian Mueller; Chief Financial Officer, Executive Vice President; Biomarin Pharmaceutical Inc Cristin ...
BioMarin Pharma Shares Rise After Higher 4Q, Upbeat Outlook
Shares of BioMarin Pharmaceutical climbed after better fourth-quarter earnings and revenue topped analyst views and the company provided upbeat revenue guidance. The stock was up 5% at $68.87 in ...